

LETTER

Open Access



# Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial

Stefano Barco<sup>1</sup> , Roland Bingisser<sup>2</sup>, Giuseppe Colucci<sup>3</sup>, André Frenk<sup>4</sup>, Bernhard Gerber<sup>5</sup>, Ulrike Held<sup>6</sup>, Francois Mach<sup>7</sup>, Lucia Mazzolai<sup>8</sup>, Marc Righini<sup>9</sup>, Thomas Rosemann<sup>10</sup>, Tim Sebastian<sup>1</sup>, Rebecca Spescha<sup>1</sup>, Stefan Stortecky<sup>4</sup>, Stephan Windecker<sup>4</sup> and Nils Kucher<sup>1\*</sup>

## Abstract

**Objectives:** The OVID study will demonstrate whether prophylactic-dose enoxaparin improves survival and reduces hospitalizations in symptomatic ambulatory patients aged 50 or older diagnosed with COVID-19, a novel viral disease characterized by severe systemic, pulmonary, and vessel inflammation and coagulation activation.

**Trial design:** The OVID study is conducted as a multicentre open-label superiority randomised controlled trial.

### Participants: Inclusion Criteria

1. Signed patient informed consent after being fully informed about the study's background.
2. Patients aged 50 years or older with a positive test for SARS-CoV2 in the past 5 days and eligible for ambulatory treatment.
3. Presence of respiratory symptoms (i.e. cough, sore throat, or shortness of breath) or body temperature  $>37.5^{\circ}\text{C}$ .
4. Ability of the patient to travel to the study centre by private transportation, performed either by an accompanying person from the same household or by the patient themselves
5. Ability to comply with standard hygiene requirements at the time of in-hospital visit, including a face mask and hand disinfectant.
6. Ability to walk from car to study centre or reach it by wheelchair transport with the help of an accompanying person from the same household also complying with standard hygiene requirements.
7. Ability to self-administer prefilled enoxaparin injections after instructions received at the study centre or availability of a person living with the patient to administer enoxaparin.

### Exclusion Criteria

1. Any acute or chronic condition posing an indication for anticoagulant treatment, e.g. atrial fibrillation, prior

(Continued on next page)

\* Correspondence: [nils.kucher@usz.ch](mailto:nils.kucher@usz.ch)

<sup>1</sup>Clinic of Angiology, University Hospital Zurich, Zurich, Switzerland

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

(Continued from previous page)

venous thromboembolism (VTE), acute confirmed symptomatic VTE, acute coronary syndrome.

2. Anticoagulant thromboprophylaxis deemed necessary in view of the patient's history, comorbidity or predisposing strong risk factors for thrombosis:

a. Any of the following events occurring in the prior 30 days: fracture of lower limb, hospitalization for heart failure, hip/knee replacement, major trauma, spinal cord injury, stroke,

b. previous VTE,

c. histologically confirmed malignancy, which was diagnosed or treated (surgery, chemotherapy, radiotherapy) in the past 6 months, or recurrent, or metastatic, or inoperable.

3. Any clinically relevant bleeding (defined as bleeding requiring hospitalization, transfusion, surgical intervention, invasive procedures, occurring in a critical anatomical site, or causing disability) within 30 days prior to randomization or sign of acute bleeding.

4. Intracerebral bleeding at any time in the past or signs/symptoms consistent with acute intracranial haemorrhage.

5. Haemoglobin <8 g/dL and platelet count <50 × 10<sup>9</sup> cells/L confirmed by recent laboratory test (<90 days).

6. Subjects with any known coagulopathy or bleeding diathesis, including known significant liver disease associated with coagulopathy.

7. Severe renal insufficiency (baseline creatinine clearance <30 mL/min calculated using the Cockcroft-Gault formula) confirmed by recent laboratory test (<90 days).

8. Contraindications to enoxaparin therapy, including prior heparin-induced thrombocytopenia and known hypersensitivity.

9. Current use of dual antiplatelet therapy.

10. Participation in other interventional studies over the past 30 days.

11. Non-compliance or inability to adhere to treatment or lack of a family environment or support system for home treatment.

12. Cognitive impairment and/or inability to understand information provided in the study information.

Patient enrolment will take place at seven Swiss centres, including five university hospitals and two large cantonal hospitals.

**Intervention and comparator:** Patients randomized to the intervention group will receive subcutaneous enoxaparin at the recommended dose of 4,000 IU anti-Xa activity (40 mg/0.4 ml) once daily for 14 days. Patients randomized to the comparator group will receive no anticoagulation.

**Main outcomes:** Primary outcome: a composite of any hospitalization or all-cause death occurring within 30 days of randomization.

Secondary outcomes: (i) a composite of cardiovascular events, including deep vein thrombosis (including catheter-associated), pulmonary embolism, myocardial infarction/myocarditis, arterial ischemia including mesenteric and extremities, acute splanchnic vein thrombosis, or ischemic stroke within 14 days, 30 days, and 90 days of randomization; (ii) each component of the primary efficacy outcome, within 14 days, 30 days, and 90 days of randomization; (iii) net clinical benefit (accounting for the primary efficacy outcome, composite cardiovascular events, and major bleeding), within 14 days, 30 days, and 90 days of enrolment; (iv) primary efficacy outcome, within 14 days, and 90 days of enrolment; (v) disseminated intravascular coagulation (ISTH criteria, in-hospital diagnosis) within 14 days, 30 days, and 90 days of enrolment.

**Randomisation:** Patients will undergo block stratified randomization (by age: 50-70 vs. >70 years; and by study centre) with a randomization ratio of 1:1 with block sizes varying between 4 and 8. Randomization will be performed after the signature of the informed consent for participation and the verification of the eligibility criteria using the electronic data capture software (REDCAP, Vanderbilt University, v9.1.24).

**Blinding (masking):** In this open-label study, no blinding procedures will be used.

**Numbers to be randomised (sample size):** The sample size calculation is based on the parameters  $\alpha = 0.05$  (2-sided), power:  $1 - \beta = 0.8$ , event rate in experimental group,  $p_{exp} = 0.09$  and event rate in control group,  $p_{con} = 0.15$ . The resulting total sample size is 920. To account for potential dropouts, the total sample size was fixed to 1000 with 500 patients in the intervention group and 500 in the control group.

(Continued on next page)

(Continued from previous page)

**Trial Status:** Protocol version 1.0, 14 April 2020. Protocol version 3.0, 18 May 2020

Recruiting start date: June 2020.

Last Patient Last Visit: March 2021.

**Trial registration:** ClinicalTrials.gov Identifier: [NCT04400799](https://clinicaltrials.gov/ct2/show/study/NCT04400799)

First Posted: May 26, 2020

Last Update Posted: July 16, 2020

**Full protocol:** The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

**Keywords:** COVID-19, Randomised controlled trial, protocol, enoxaparin, anticoagulation, elderly, venous thromboembolism, thrombosis, prevention

## Supplementary information

**Supplementary information** accompanies this paper at <https://doi.org/10.1186/s13063-020-04678-4>.

### Additional file 1.

## Acknowledgements

The authors would like to thank the Clinical Trial Centre from the University Hospital Zurich for their support and collaboration. The authors also thank the study nurses, clinical study management teams and local investigators from all the participating centres for their invaluable contribution towards the successful set-up of this study.

## Authors' contributions

SB and NK conceived and designed the study. SB, UH, and NK verified the analytical methods. SB, RB, GC, AF, BG, UH, FM, LM, MR, TR, TS, RS, SS, SW, and NK discussed and revised the study protocol, and contributed to this final manuscript. The author(s) read and approved the final manuscript.

## Funding

The authors received public funding from the Schweizerischer Nationalfonds (SNF; NFP 78 Covid-19; Project ID 198352; <https://data.snf.ch/covid-19/snsf/198352>), the Innovation Pool of the University Hospital Zurich and from the "Forschungsförderung" from the University Zurich, respectively. Additionally, a private funding from the Dürrmüller Bol Foundation was obtained. Funding was used to design and set up the study, including the payment of collaborators. The funding bodies had no influence on the study design and will have no influence on the study conductance or publication decisions.

## Availability of data and materials

All the Steering Committee members and co-authors will have access to the original dataset. The data will be available from the author on reasonable request ([nils.kucher@usz.ch](mailto:nils.kucher@usz.ch)).

## Ethics approval and consent to participate

The central ethical committee (cantonal ethic committee Zurich) approved the study on May 28, 2020 (BASEC-No: 2020-01157) after the initial submission on April 15, 2020. The authors received approval for the centres in Basel, Bern and Geneva. On June 4, 2020, the ethical commission approved the remaining centres, Lausanne, Lugano and Bellinzona. The authors certify that this trial has received ethical approval from the appropriate ethical committee as described above. All eligible patients receive written information about the study before giving their written informed consent to participate in the study.

## Consent for publication

Not applicable.

## Competing interests

The authors declare that they have no competing interests for the present work.

## Author details

<sup>1</sup>Clinic of Angiology, University Hospital Zurich, Zurich, Switzerland. <sup>2</sup>Emergency Department, University Hospital Basel, Basel, Switzerland. <sup>3</sup>Service of Haematology, Clinica Luganese Moncucco, Lugano, Switzerland. <sup>4</sup>Department of Cardiology, Inselspital Bern, University of Bern, Bern, Switzerland. <sup>5</sup>Clinic of Haematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland. <sup>6</sup>Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland. <sup>7</sup>Cardiology Division, Geneva University Hospital, Geneva, Switzerland. <sup>8</sup>Department of Angiology, Lausanne University Hospital, Lausanne, Switzerland. <sup>9</sup>Division of Angiology and Haemostasis, Department of Medical Specialties, Geneva University Hospital, Geneva, Switzerland. <sup>10</sup>Institute of Primary Care, University of Zurich, Zurich, Switzerland.

Received: 7 August 2020 Accepted: 12 August 2020

Published online: 09 September 2020

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

